[
  {
    "ts": null,
    "headline": "Colgate-Palmolive, Rocket, Regeneron: Trending Tickers",
    "summary": "Colgate-Palmolive (CL) stock is in focus after the company warned of a \"persistently cautious consumer\" in North America, even as it reported strong second quarter results and announced cost-cutting initiatives to boost long-term growth. Rocket Companies (RKT) stock is rising on strong second quarter earnings and upbeat third quarter guidance, seeing demand expected to accelerate through the extended home-buying season. Regeneron (REGN) reported second quarter adjusted earnings per share that came in above estimates, driven by strong sales of its drug Eylea HD. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=ee1de8ccf88db94d02d1c35facfb38d18ad85ae0f5d4a9c9285cd3816bd68e7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754078238,
      "headline": "Colgate-Palmolive, Rocket, Regeneron: Trending Tickers",
      "id": 136183546,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Colgate-Palmolive (CL) stock is in focus after the company warned of a \"persistently cautious consumer\" in North America, even as it reported strong second quarter results and announced cost-cutting initiatives to boost long-term growth. Rocket Companies (RKT) stock is rising on strong second quarter earnings and upbeat third quarter guidance, seeing demand expected to accelerate through the extended home-buying season. Regeneron (REGN) reported second quarter adjusted earnings per share that came in above estimates, driven by strong sales of its drug Eylea HD. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=ee1de8ccf88db94d02d1c35facfb38d18ad85ae0f5d4a9c9285cd3816bd68e7f"
    }
  },
  {
    "ts": null,
    "headline": "Why Regeneron (REGN) Stock Is Trading Up Today",
    "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst expectations. The pharmaceutical giant posted earnings per share of $12.89, which crushed the forecast of $8.50. Revenue also beat projections, totaling $3.68 billion against an expected $3.29 billion. This performance marked a notable rebound from the prior quarter. The growth stemmed from strong sales of key",
    "url": "https://finnhub.io/api/news?id=c6b217abbdca6312c116e55808f03946ddf854f545c01176e2adee7041cb4683",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754065537,
      "headline": "Why Regeneron (REGN) Stock Is Trading Up Today",
      "id": 136183583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst expectations. The pharmaceutical giant posted earnings per share of $12.89, which crushed the forecast of $8.50. Revenue also beat projections, totaling $3.68 billion against an expected $3.29 billion. This performance marked a notable rebound from the prior quarter. The growth stemmed from strong sales of key",
      "url": "https://finnhub.io/api/news?id=c6b217abbdca6312c116e55808f03946ddf854f545c01176e2adee7041cb4683"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Rapidly Decreasing Importance Of Eylea",
    "summary": "Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.",
    "url": "https://finnhub.io/api/news?id=d5cb9bd425d2606813dd3ada36d7b958c73bc3ff94a8ecae486367615b9a48b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754064332,
      "headline": "Regeneron: Rapidly Decreasing Importance Of Eylea",
      "id": 136178284,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153982109/image_2153982109.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.",
      "url": "https://finnhub.io/api/news?id=d5cb9bd425d2606813dd3ada36d7b958c73bc3ff94a8ecae486367615b9a48b0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up",
    "summary": "REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.",
    "url": "https://finnhub.io/api/news?id=2c1ac47d22226c5d928a355a49d67b51a3e598dc85cc64ff87c181017e8c2765",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754061000,
      "headline": "Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up",
      "id": 136167124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.",
      "url": "https://finnhub.io/api/news?id=2c1ac47d22226c5d928a355a49d67b51a3e598dc85cc64ff87c181017e8c2765"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Slump on Tariffs and Weak US Job Growth",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures...",
    "url": "https://finnhub.io/api/news?id=d0b5022825f76d5d648cea23db874fa76af76372001e1c23b4f4f8535494e264",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754057412,
      "headline": "Stocks Slump on Tariffs and Weak US Job Growth",
      "id": 136164945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures...",
      "url": "https://finnhub.io/api/news?id=d0b5022825f76d5d648cea23db874fa76af76372001e1c23b4f4f8535494e264"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ETCompany ParticipantsChristopher R.",
    "url": "https://finnhub.io/api/news?id=ae9ba290ef3747881b0b0a776d7820883bc76d18aee03fee2adf9450ae4f5362",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754055970,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript",
      "id": 136168798,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ETCompany ParticipantsChristopher R.",
      "url": "https://finnhub.io/api/news?id=ae9ba290ef3747881b0b0a776d7820883bc76d18aee03fee2adf9450ae4f5362"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates",
    "summary": "Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=6fbd1a425422639ac2657c53775e37c098e5519bfeafbcdd41448edb578c917a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754055004,
      "headline": "Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates",
      "id": 136165673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=6fbd1a425422639ac2657c53775e37c098e5519bfeafbcdd41448edb578c917a"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines",
    "summary": "On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57. The company reported sales of $3.68 billion, up 4% year over year, beating the consensus of $3.29 billion. In the second quarter, U.S. net sales for Eylea HD and Eylea decreased 25% year-over-year to $1.15 billion, including $393 million from Eylea HD and $754 million from Eylea. Also Read: Regeneron’s Obesity Trial With Nov",
    "url": "https://finnhub.io/api/news?id=00474a6a1377b36fb18ee11401bf68324981b05218932ef46d6ce3e1988ee996",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754054566,
      "headline": "Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines",
      "id": 136165674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57. The company reported sales of $3.68 billion, up 4% year over year, beating the consensus of $3.29 billion. In the second quarter, U.S. net sales for Eylea HD and Eylea decreased 25% year-over-year to $1.15 billion, including $393 million from Eylea HD and $754 million from Eylea. Also Read: Regeneron’s Obesity Trial With Nov",
      "url": "https://finnhub.io/api/news?id=00474a6a1377b36fb18ee11401bf68324981b05218932ef46d6ce3e1988ee996"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping.",
    "summary": "U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in the quarter from last year",
    "url": "https://finnhub.io/api/news?id=75895c0ef1021377d83751fb2267f2b782e9b556eb7760729bf8cda9c572490e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754054160,
      "headline": "Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping.",
      "id": 136165675,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in the quarter from last year",
      "url": "https://finnhub.io/api/news?id=75895c0ef1021377d83751fb2267f2b782e9b556eb7760729bf8cda9c572490e"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron posts better-than-expected Q2 results, downplays tariff impact",
    "summary": "(Reuters) -Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on imports from the European Union.  As the company gains clarity on details of the agreement and other potential tariffs, CEO Leonard Schleifer said the 15% duties were not expected to have a material impact.  Investors have set a high bar for Regeneron and French partner Sanofi's Dupixent, one of the U.S. drugmaker's growth drivers.",
    "url": "https://finnhub.io/api/news?id=39bc61f8e95a0c7f0ed52875e43f9c466d18247dbb9693ba4a570270b8a5605a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754050911,
      "headline": "Regeneron posts better-than-expected Q2 results, downplays tariff impact",
      "id": 136165676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "(Reuters) -Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on imports from the European Union.  As the company gains clarity on details of the agreement and other potential tariffs, CEO Leonard Schleifer said the 15% duties were not expected to have a material impact.  Investors have set a high bar for Regeneron and French partner Sanofi's Dupixent, one of the U.S. drugmaker's growth drivers.",
      "url": "https://finnhub.io/api/news?id=39bc61f8e95a0c7f0ed52875e43f9c466d18247dbb9693ba4a570270b8a5605a"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron shares edge higher as second quarter earnings surpass estimates",
    "summary": "Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus estimate. Revenue also beat forecasts, coming in at $3.68 billion versus the expected $3.28 billion.",
    "url": "https://finnhub.io/api/news?id=a80b37bd3edf3bb5a280f13a0d301be20cf2b2ba0256620f62fd3e4a69a5bd74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754048788,
      "headline": "Regeneron shares edge higher as second quarter earnings surpass estimates",
      "id": 136165677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus estimate. Revenue also beat forecasts, coming in at $3.68 billion versus the expected $3.28 billion.",
      "url": "https://finnhub.io/api/news?id=a80b37bd3edf3bb5a280f13a0d301be20cf2b2ba0256620f62fd3e4a69a5bd74"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates",
    "summary": "Regeneron (REGN) delivered earnings and revenue surprises of +60.52% and +9.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=636c93e67cea5fa936af6ea93f483c30f8292898430bf76052c5e180254cb9d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754048702,
      "headline": "Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates",
      "id": 136165678,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) delivered earnings and revenue surprises of +60.52% and +9.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=636c93e67cea5fa936af6ea93f483c30f8292898430bf76052c5e180254cb9d2"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron cancer bispecific rejected again; Allogene discloses trial death",
    "summary": "The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.",
    "url": "https://finnhub.io/api/news?id=b6ab9cbe247e43536b500d992a8c39b937fd7e4ee56077f59e321a55f231d03c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754046600,
      "headline": "Regeneron cancer bispecific rejected again; Allogene discloses trial death",
      "id": 136166550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.",
      "url": "https://finnhub.io/api/news?id=b6ab9cbe247e43536b500d992a8c39b937fd7e4ee56077f59e321a55f231d03c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Q2 Earnings Snapshot",
    "summary": "TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. REGN) on Friday reported second-quarter earnings of $1.39 billion. The Tarrytown, New York-based company said it had profit of $12.81 per share.",
    "url": "https://finnhub.io/api/news?id=544687faae872ad340ee6eff4f353528384b9f37c634f94f9d21001b6099cb79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754044919,
      "headline": "Regeneron: Q2 Earnings Snapshot",
      "id": 136165680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. REGN) on Friday reported second-quarter earnings of $1.39 billion. The Tarrytown, New York-based company said it had profit of $12.81 per share.",
      "url": "https://finnhub.io/api/news?id=544687faae872ad340ee6eff4f353528384b9f37c634f94f9d21001b6099cb79"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron’s (NASDAQ:REGN) Q2: Strong Sales",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was 52.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=ebdebac6768c36a04e4f49a3ba54faed8cb9b9937ea499bb70307285763e0fd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754044919,
      "headline": "Regeneron’s (NASDAQ:REGN) Q2: Strong Sales",
      "id": 136165679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was 52.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=ebdebac6768c36a04e4f49a3ba54faed8cb9b9937ea499bb70307285763e0fd2"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Reports Second Quarter 2025 Financial and Operating Results",
    "summary": "Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA® U.S. net sales decreased 25% to $1.15 billion GAAP EPS increased 3% to $12.81; non-GAAP EPS(a) increased 12% to $12.89FDA approved Lynozyfic™ (linvoseltamab) for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spon",
    "url": "https://finnhub.io/api/news?id=9ebc656073af4d122dc9164afa1bc94d1b04599ee46dd9394d8a70326e980087",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754044200,
      "headline": "Regeneron Reports Second Quarter 2025 Financial and Operating Results",
      "id": 136165681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA® U.S. net sales decreased 25% to $1.15 billion GAAP EPS increased 3% to $12.81; non-GAAP EPS(a) increased 12% to $12.89FDA approved Lynozyfic™ (linvoseltamab) for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spon",
      "url": "https://finnhub.io/api/news?id=9ebc656073af4d122dc9164afa1bc94d1b04599ee46dd9394d8a70326e980087"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's Eylea HD, Odronextamab Applications Hit FDA Snag",
    "summary": "Regeneron's Eylea HD, Odronextamab Applications Hit FDA Snag",
    "url": "https://finnhub.io/api/news?id=d6119c0f6547195dacd759128ae5bf2ce3f8c9dd34184d5f92f8987d0d671e36",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754035620,
      "headline": "Regeneron's Eylea HD, Odronextamab Applications Hit FDA Snag",
      "id": 136223704,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron's Eylea HD, Odronextamab Applications Hit FDA Snag",
      "url": "https://finnhub.io/api/news?id=d6119c0f6547195dacd759128ae5bf2ce3f8c9dd34184d5f92f8987d0d671e36"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron 2Q Revenue, Adjusted EPS Top Estimates",
    "summary": "Regeneron 2Q Revenue, Adjusted EPS Top Estimates",
    "url": "https://finnhub.io/api/news?id=a41523efc423d7be9743bc891f7b6f7fac66cffda8621705170f57abdb0c5a66",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754032680,
      "headline": "Regeneron 2Q Revenue, Adjusted EPS Top Estimates",
      "id": 136223705,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron 2Q Revenue, Adjusted EPS Top Estimates",
      "url": "https://finnhub.io/api/news?id=a41523efc423d7be9743bc891f7b6f7fac66cffda8621705170f57abdb0c5a66"
    }
  },
  {
    "ts": null,
    "headline": "Chevron and Exxon Mobil head earnings for Friday",
    "summary": "Chevron and Exxon Mobil head earnings for Friday",
    "url": "https://finnhub.io/api/news?id=072bfd67f05d12d49e347233b6e4467bf0ac5d1c25b7f2b28db57733bcae61e6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754029145,
      "headline": "Chevron and Exxon Mobil head earnings for Friday",
      "id": 136175020,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Chevron and Exxon Mobil head earnings for Friday",
      "url": "https://finnhub.io/api/news?id=072bfd67f05d12d49e347233b6e4467bf0ac5d1c25b7f2b28db57733bcae61e6"
    }
  },
  {
    "ts": null,
    "headline": "Trump doubles down on Most Favored Nation plan to target drug prices",
    "summary": "Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.",
    "url": "https://finnhub.io/api/news?id=caa6f76ac187f7e7b18c00b896f616e50ea68bcbacfbe1ae0a2120c6d6cb861c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754008407,
      "headline": "Trump doubles down on Most Favored Nation plan to target drug prices",
      "id": 136160868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.",
      "url": "https://finnhub.io/api/news?id=caa6f76ac187f7e7b18c00b896f616e50ea68bcbacfbe1ae0a2120c6d6cb861c"
    }
  }
]